Multiple myelomais a highly malignant hematological disease and is hardly cured with conventional chemotherapy. Although high-dose chemotherapy with autologous stem cell transplantation increases the complete remission rate and improves event free survival and over all survival (1, 2), there is no plateau of the survival curves and manypatients still relapse (3, 4). Therefore several strategies concerning the methods of transplantation, such as the conditioning regimen, number of transplantations, source of stem cells and allogeneic transplantation, are under investigation to improve the treatment results.
Manymalignant neoplasms such as breast, prostate and non small cell lung cancers are dependent on neovascularization to sustain growth. Recently increased blood vessel formation (angiogenesis) in the bone marrow of the patients with multiple myelomawas reported (5) and elevated levels of several angiogenic cytokines in patients with myeloma was also reported (6). In 1994, D'Amato et al (7) reported that orally administered thalidomide was an inhibitor of angiogenesis induced by basic fibroblast growth factor in a rabbit cornea micropocket assay. Thalidomide was developed as a sedative but was proven to be a potent teratogen seen in babies with limb defects in association with maternal thalidomide usage. They revealed that the limb defects seen with thalidomide were secondary to an inhibition of blood vessel growth in the developing fetal limb bud caused by the antiangiogenic activity of thalidomide. From these considerations, Singhal et al (8) performed a clinical trial of thalidomide as a single agent in patients with advanced and refractory myeloma. The overall response rate was 32%
which was associated with a decreased number of plasma cells in bone marrow and increased hemoglobin levels. After a median follow-up of 14.5 months, the median time to progression had not been reached. Considering that these patients had relapsed after chemotherapy, 90%with a relapse after high-dose chemotherapy, these effects of thalidomide is magnificent. On the other hand, many patients suffered from troublesome side effects such as weakness, fatigue, somnolence, neuropathy and constipation especially at the higher dose of thalidomide. Also it is unclear whether there is a dose-response relationship with its effectiveness. Therefore, it is necessary to determine the optimal dose of thalidomide and the schedule of administration. In this issue, Hayashi et al (9) reported a patient with IgD myelomaand renal failure requiring chronic hemodialysis who responded to thalidomide. IgD multiple myelomais often accompanied by renal failure and shows poor prognosis. The authors revealed that thalidomide treatment is also effective for IgD myelomaas it is for other types of myelomas. Concerning the thalidomide therapy against myelomawith renal failure, especially in chronic hemodialysis, there is no report yet. This is the first report on thalidomide therapy in a patient receiving chronic hemodialysis.
See also p 605.
Thalidomide has been shown to inhibit angiogenesis induced by fibroblast growth factor (7). Nevertheless, Singhal et al (8) found no correlation between the microvascular density of bone marrow and the response to thalidomide. These findings suggest that other mechanismsmaywork in addition to inhibition of angiogenesis in the usage of thalidomide for multiple myeloma.Thalidomide is known to have a broad spectrum of pharmacologic and immunologic effects (10) . Thalidomide directly induces either apoptosis or Gi growth arrest in myeloma cells and enhances the antimyeloma activity of dexamethasone (1 1 
